ArticleGynecologic oncology2025

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Amma Asare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.